Literature DB >> 21042726

Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women.

Sophia Brismar Wendel1, Tove Kaldensjö, Pernilla Peterson, Sonia Andersson, Kristina Broliden, Taha Hirbod.   

Abstract

Persistent human papillomavirus (HPV) infection is a prerequisite for cervical cancer and results from bypassing the local immune response. Twenty-four volunteers underwent an ectocervical biopsy, Pap smear, tests for sexually transmitted infections including HIV and HPV genotyping. All answered a questionnaire regarding medical history. Repeat Pap smear and HPV genotyping was performed 9-26 months later. Quantitative reverse transcriptase (qRT-)PCR was used to assess expression of CD3, CD4, CD8, CD19, CD27, IL-2, IL-12, IL-4, IL-10, IL-17, HLA-DRα, TGFβ, IFNγ, PD-1, PD-L1, CTLA-4, LAG3, IgA, IgG, CCR5, CCL5/RANTES and the IL-7 receptor in the biopsies. Eleven of 24 volunteers were HPV DNA-positive at baseline. Four of 10 were infected with a persistent HPV genotype at follow-up. All target molecules were successfully amplified and quantified except for IL-4. We found no difference in mRNA expression of these molecules when comparing HPV DNA-positive and -negative women, neither when comparing persistently infected individuals or those who cleared the infection. However, mRNA expression of the B cell phenotypic marker CD19 was higher in women using hormonal contraception than those not (p<0.05). HPV infection does not evoke a local inflammatory immune response in the ectocervix measurable with qRT-PCR. Hormonal contraception may influence B cell activity in the cervix.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21042726     DOI: 10.3892/ijo_00000810

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

2.  Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.

Authors:  Mark E Scott; Yurii B Shvetsov; Pamela J Thompson; Brenda Y Hernandez; Xuemei Zhu; Lynne R Wilkens; Jeffrey Killeen; Dien D Vo; Anna-Barbara Moscicki; Marc T Goodman
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

3.  Presence of CD8+ T cells in the ectocervical mucosa correlates with genital viral shedding in HIV-infected women despite a low prevalence of HIV RNA-expressing cells in the tissue.

Authors:  Anna Gibbs; Taha Hirbod; Qingsheng Li; Karin Bohman; Terry B Ball; Francis A Plummer; Rupert Kaul; Joshua Kimani; Kristina Broliden; Annelie Tjernlund
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

4.  Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression.

Authors:  Annelie Tjernlund; Ann M Carias; Sonia Andersson; Susanna Gustafsson-Sanchez; Maria Röhl; Pernilla Petersson; Andrea Introini; Thomas J Hope; Kristina Broliden
Journal:  Biol Reprod       Date:  2015-01-14       Impact factor: 4.285

5.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  Feasibility and safety of cervical biopsy sampling for mucosal immune studies in female sex workers from Nairobi, Kenya.

Authors:  Klara Hasselrot; Juliana Cheruiyot; Joshua Kimani; Terry B Ball; Rupert Kaul; Taha Hirbod
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.